Catalyst Funds Management Pty Ltd Lowers Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Catalyst Funds Management Pty Ltd reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,770 shares of the biopharmaceutical company’s stock after selling 8,430 shares during the quarter. Alnylam Pharmaceuticals comprises about 1.0% of Catalyst Funds Management Pty Ltd’s holdings, making the stock its 15th biggest holding. Catalyst Funds Management Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,512,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $30,000. Ameritas Advisory Services LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $42,000. AlphaQuest LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $43,000. Finally, Parkside Financial Bank & Trust grew its position in Alnylam Pharmaceuticals by 32.6% during the second quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 44 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.3%

Shares of ALNY opened at $460.76 on Thursday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market cap of $60.87 billion, a price-to-earnings ratio of -186.54 and a beta of 0.30. The firm has a 50 day moving average price of $458.35 and a 200-day moving average price of $388.21. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 3,022 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the transaction, the executive vice president directly owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. This trade represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 78,328 shares of company stock valued at $35,705,793. 1.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Jefferies Financial Group dropped their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a research note on Monday, October 6th. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.